Xenetic Biosciences Stock Price, News & Analysis (NASDAQ:XBIO)

$1.99 +0.10 (+5.29 %)
(As of 02/19/2018 11:13 AM ET)
Previous Close$1.89
Today's Range$1.97 - $2.19
52-Week Range$1.75 - $5.90
Volume2,200 shs
Average Volume20,109 shs
Market Capitalization$17.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22

About Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences logoXenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XBIO
CUSIPN/A
Phone781-778-7720

Debt

Debt-to-Equity RatioN/A
Current Ratio0.94%
Quick Ratio0.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3 million
Price / Sales5.78
Cash FlowN/A
Price / CashN/A
Book Value$1.95 per share
Price / Book1.02

Profitability

Trailing EPS($1.24)
Net Income$-54,200,000.00
Net MarginsN/A
Return on Equity-64.21%
Return on Assets-46.31%

Miscellaneous

Employees7
Outstanding Shares8,720,000

Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.03. The business earned $0.09 million during the quarter. View Xenetic Biosciences' Earnings History.

Who are some of Xenetic Biosciences' key competitors?

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the folowing people:

  • Jeffrey F. Eisenberg, Chief Executive Officer, Chief Operating Officer, Director (Age 51)
  • James F. Parslow, Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer (Age 52)
  • Curtis A. Lockshin Ph.D., Chief Scientific Officer (Age 56)
  • Colin William Hill, Treasurer, Secretary, Director (Age 69)
  • Timothy R. Cote M.D., Director (Age 54)
  • Firdaus Jal Dastoor, Director (Age 62)
  • Artur Aleksandrovich Isaev, Director (Age 47)
  • Roman Knyazev, Director (Age 35)
  • Roger D. Kornberg Ph.D., Director (Age 69)

How do I buy Xenetic Biosciences stock?

Shares of Xenetic Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of Xenetic Biosciences stock can currently be purchased for approximately $1.99.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $17.35 million and generates $3 million in revenue each year. The company earns $-54,200,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Xenetic Biosciences employs 7 workers across the globe.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 99 HAYDEN AVENUE SUITE 230, LEXINGTON MA, 02421. The company can be reached via phone at 781-778-7720.


MarketBeat Community Rating for Xenetic Biosciences (XBIO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Xenetic Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xenetic Biosciences (NASDAQ:XBIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$10.00$10.00
Price Target Upside: N/AN/AN/AN/A

Xenetic Biosciences (NASDAQ:XBIO) Consensus Price Target History

Price Target History for Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Xenetic Biosciences (NASDAQ:XBIO) Earnings History and Estimates Chart

Earnings by Quarter for Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ XBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017($0.23)($0.26)$0.09 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.21)($0.34)ViewN/AView Earnings Details
5/16/2017Q1 2017($0.21)($0.34)ViewN/AView Earnings Details
4/3/2017Q4 2016($0.28)ViewN/AView Earnings Details
11/15/2016Q3 2016($0.28)ViewN/AView Earnings Details
8/15/2016Q2 2016($5.55)ViewN/AView Earnings Details
5/16/2016Q1 2016($0.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Xenetic Biosciences (NASDAQ:XBIO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Xenetic Biosciences (NASDAQ:XBIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xenetic Biosciences (NASDAQ XBIO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Xenetic Biosciences (NASDAQ XBIO) News Headlines

Source:
DateHeadline
How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?
finance.yahoo.com - February 6 at 8:59 AM
Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?
finance.yahoo.com - January 20 at 10:30 AM
Zacks: Xenetic Biosciences Inc (XBIO) Receives Average Rating of "Strong Buy" from BrokeragesZacks: Xenetic Biosciences Inc (XBIO) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 9 at 7:32 AM
Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?
finance.yahoo.com - January 2 at 5:11 PM
 Xenetic Biosciences Inc (XBIO) Receives Consensus Recommendation of "Strong Buy" from Brokerages Xenetic Biosciences Inc (XBIO) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 24 at 9:53 PM
Zacks: Xenetic Biosciences Inc (XBIO) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Xenetic Biosciences Inc (XBIO) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - December 21 at 5:40 PM
Who Really Owns Xenetic Biosciences Inc (XBIO)?Who Really Owns Xenetic Biosciences Inc (XBIO)?
finance.yahoo.com - December 8 at 4:23 PM
Zacks: Xenetic Biosciences Inc (XBIO) Given Consensus Recommendation of "Strong Buy" by AnalystsZacks: Xenetic Biosciences Inc (XBIO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 6 at 3:34 PM
Does Xenetic Biosciences Inc’s (XBIO) 83.8% Earnings Growth Make It An Outperformer?Does Xenetic Biosciences Inc’s (XBIO) 83.8% Earnings Growth Make It An Outperformer?
finance.yahoo.com - December 1 at 5:47 PM
Analyzing Xenetic Biosciences (XBIO) & Its RivalsAnalyzing Xenetic Biosciences (XBIO) & Its Rivals
www.americanbankingnews.com - November 23 at 1:28 PM
Zacks: Xenetic Biosciences, Inc. (XBIO) Given Average Rating of "Strong Buy" by BrokeragesZacks: Xenetic Biosciences, Inc. (XBIO) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 21 at 9:52 AM
Zacks: Xenetic Biosciences, Inc. (XBIO) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Xenetic Biosciences, Inc. (XBIO) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 16 at 3:52 PM
Xenetic Biosciences, Inc. (XBIO) Releases Quarterly  Earnings Results, Misses Expectations By $0.03 EPSXenetic Biosciences, Inc. (XBIO) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - November 16 at 9:45 AM
Xenetic Biosciences Q3 Loss NarrowsXenetic Biosciences Q3 Loss Narrows
www.rttnews.com - November 16 at 8:57 AM
Xenetic Biosciences, Inc. (XBIO) Scheduled to Post Quarterly Earnings on MondayXenetic Biosciences, Inc. (XBIO) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:54 AM
Xenetic Biosciences, Inc. (XBIO) Rating Lowered to Hold at Zacks Investment ResearchXenetic Biosciences, Inc. (XBIO) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 2:24 PM
Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEOXenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
www.streetinsider.com - November 1 at 10:57 AM
How Should You Think About Xenetic Biosciences Inc’s (XBIO) Risks?How Should You Think About Xenetic Biosciences Inc’s (XBIO) Risks?
finance.yahoo.com - October 4 at 2:35 PM
Xenetic Biosciences Provides Update on Annual Meeting of StockholdersXenetic Biosciences Provides Update on Annual Meeting of Stockholders
finance.yahoo.com - October 3 at 3:31 PM
Xenetic Biosciences, Inc. (XBIO) Releases Quarterly  Earnings Results, Misses Estimates By $0.13 EPSXenetic Biosciences, Inc. (XBIO) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - August 16 at 11:32 AM
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business UpdateXenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
finance.yahoo.com - August 15 at 8:32 AM
BRIEF-Xenetic Biosciences reports Q1 loss per share $0.34BRIEF-Xenetic Biosciences reports Q1 loss per share $0.34
www.reuters.com - May 17 at 12:15 AM
XENETIC BIOSCIENCES, INC. Files SEC form 10-K, Annual ReportXENETIC BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 1 at 11:28 AM
XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal YearXENETIC BIOSCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
biz.yahoo.com - February 27 at 5:32 PM
7:05 am Xenetic receives $3 mln milestone payment from Shire (<a href="/q?s=shpg" name="shpg">SHPG</a>) for PSA-recombinant SHP656 in development for long-acting treatment for Hemophilia7:05 am Xenetic receives $3 mln milestone payment from Shire (SHPG) for PSA-recombinant SHP656 in development for long-acting treatment for Hemophilia
us.rd.yahoo.com - January 7 at 6:34 AM
Xenetic Biosciences (XBIO) Names Curtis Lockshin as CSOXenetic Biosciences (XBIO) Names Curtis Lockshin as CSO
www.streetinsider.com - January 6 at 6:41 AM
XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, OtXENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
biz.yahoo.com - January 5 at 7:38 AM

SEC Filings

Xenetic Biosciences (NASDAQ:XBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Xenetic Biosciences (NASDAQ XBIO) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.